Search filters

Filters
Clear All

Phase

  • 6
  • 9
  • 3
  • 5
  • 13
  • 44
  • 17
  • 1
  • 43

Found 44 HIV trials

A listing of HIV medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Long Acting Therapy to Improve Treatment SUccess in Daily LifE (The LATITUDE Study)
18 years - 70 years
All genders
Phase 3
This study is meant for patients who have difficulty taking their HIV meds as prescribed.  One goal of the study is to test the effectiveness of long-acting antiretroviral therapy (ART) -- a once-a-month injection that replaces daily ART pills. You will also receive compensation for participating in this study, with …
99 years or below
All genders
Both HIV infection and exposure to opioids, including intravenous heroin in people who inject drugs (PWIDs), are associated with systemic immune activation due to, at least partially, dysbiosis and increased microbial translocation from the gut. Medication-assisted treatment (MAT) approaches based on the administration of Opioid Receptor (MOR) agonists (e.g. methadone) …
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy
99 years or below
All genders
Phase 1
A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …
 Adherence to HIV Therapy in Heroin Addicts Oral vs. Extended Release Naltrexone-Test
18 years - 64 years
All genders
Phase 2
Interventional
Substance use, particularly the compulsive behaviors associated with addiction, lead to unhealthy behaviors including non-adherence to antiretroviral therapy (ART) and treatment failure. High on the list of disorders leading to non-adherence is heroin addiction as a wide range of impulsive, high-risk behaviors accompanies it. The science of adherence would be …
 Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
18 years - 99 years
All genders
Phase 2
Interventional
This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
 AMC 083 / UPCC 12716: Tissue Acquisition for Analysis of Prognostic Factors  Immunology  and Genetic Progression of HIV-1 Associated Malignancies
18 years - 99 years
All genders
The main purpose of this study is to collect tissue from people diagnosed with HIV-associated cancer. We will use these samples to look for genetic changes associated with HIV- and other virus-related cancers. This may lead to better ways of preventing, detecting, and treating HIV-associated cancers.
99 years or below
All genders
Phase 1
Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or …
99 years or below
All genders
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
21 - 30 of 44